Abstract
Objectives: To review the effects of aripiprazole in treatment of medication induced tardive dyskinesaMethods: Medline search was was performed using key words of 'aripiprazole' and 'tardive dyskinesia', we searched overall articles published between 2000 and 2008.Result: Aripiprazole inhibits central dopaminergic neuron activity by a partial agonistic effects on presynaptic D2 dopamine autoreceptors and also acts as an antagonist at postsynaptic D2 dopamine receptors. Through this mechanism, aripiprazole exerts activity as a dopaminergic agonist in hypodopaminergic states, while acting as a dopamine antagonist when dopaminergic activity is increased. There is also evidence from basic science studies that aripiprazole causes D2 receptor up-regulationConclusions: It is plausible that aripiprazole, by virtue of its dopamine agonistic activity, can potentially normalize D2 dopamine receptor up-regulation, this properties may play a role in both prevention of the emergence of tardive dyskinesia and the treatment of Tardive dyskinesia. Double blind placebo-controlled studies would be needed to enlighten this issues.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
